Background: Post intubation cardiac arrest and hemodynamic instability are serious adverse events encountered in critically ill patients. The association of pre-existing right ventricular (RV) dysfunction with post intubation cardiac arrest and hemodynamic instability in critically ill patients is unknown. Methods: This is a retrospective matched cohort study of adult critically ill patients who underwent intubation from July 2016 to December 2019. The study was conducted at a quaternary medical center in Houston, Texas. A total of 340 critically ill patients who underwent intubation in the intensive care units, wards, and the emergency room were included. The study cohort was categorized into 4 groups based on the pre-existing RV function: normal function, mild dysfunction, moderate dysfunction, and severe dysfunction. Cardiac arrest and/or hemodynamic instability within one hour post intubation were the primary study outcomes. Secondary outcomes included in hospital and 60-day mortality. Results: Study patients were of mean age of 61.95 ± 14.28 years, including 132 (39%) females and 208 (61%) males. The primary outcomes were significantly worse in mild, moderate, and severe RV dysfunction groups compared to the normal RV function group (34.12%-P = 0.014, 47.06%-P < 0.001, 51.67%-P < 0.001, vs. 17.56%). In a multivariable logistic regression analysis, pre-existing moderate (OR = 2.65, P = 0.013) and severe RV dysfunction groups (OR = 2.66, P = 0.015) were associated with statistically significant higher cardiac arrest and hemodynamic instability post intubation. Pre-existing severe RV dysfunction was associated with statistically significant higher in hospital mortality (62.35%-P < 0.001). The multivariable Cox-regression analysis showed that pre-existing severe RV dysfunction was associated with a statistically significant higher 60-day mortality (HR = 2.57, P = 0.001). Conclusions: Pre-existing moderate and severe RV dysfunctions were independently associated with significantly higher cardiac arrest and/or hemodynamic instability post intubation in critically ill patients. Pre-existing RV function may serve as a mortality predictor in critically ill patients undergoing endotracheal intubation.
RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) is shown to block replication of the SARS-CoV-2 virus and has been granted Fast Track Designation by the US FDA for the treatment of Critical COVID-19 with Respiratory Failure. We describe the clinical course of the first patient treated with this investigational medication in an open label manner -- a 54 year old patient suffering antibody-mediated rejection of his double lung transplant who contracted COVID-19 with respiratory failure refractory to all currently available therapies. He received three infusions of RLF-100 under an FDA-approved emergency use IND. Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted. He was discharged from intensive care at that point and scheduled for discharge to home at 1 week on room air. Despite an intervening hospitalization for trauma, he remains alive and free of respiratory failure at 28 days post treatment.
Background: Symptomatic aortic stenosis (AS) constitutes a class I indication for aortic valve intervention, either by surgical or transcatheter aortic valve replacement (TAVR). Progressive AS can reduce maximal oxygen consumption (MVO2), yet this parameter is not routinely evaluated in clinical practice. Case summary: We present a case of a 68-year-old with hypertension and hyperlipidaemia, initially diagnosed with moderate AS [aortic valve area (AVA) 1.3 cm2, mean gradient 23 mmHg, peak velocity 3.2 m/s]. He was asymptomatic and maintained a high level of physical activity, including treadmill running. Over the course of 3 years, the patient used an Apple Watch® to monitor estimated VO2 max. Despite stable exercise tolerance, his recorded VO2 max decreased progressively from 36 to 26 mL/kg/min. Concerned by the trend, he sought our evaluation. Repeat echocardiography showed severe AS (AVA 0.6 cm2, mean gradient 43 mmHg, peak velocity 4.29 m/s) with preserved left ventricular ejection fraction (LVEF 60%–65%). The patient subsequently underwent TAVR with a 26 mm Edwards Lifesciences Sapien 3 Ultra Valve®. At 1-year follow-up, his Apple Watch–derived VO2 max improved to 41 mL/kg/min. Echocardiography confirmed a well-seated prosthesis with a mean gradient of 9 mmHg. Discussion: This case illustrates the potential utility of consumer wearable technology (Apple Watch) for detecting progressive asymptomatic AS using estimated VO2 max feature. Continuous tracking of estimated VO2 max may serve as an adjunct parameter to guide timing of intervention in selected patients.